Recardio at ESC Congress 2026
- 2 days ago
- 1 min read
San Francisco, July 29, 2026 - Recardio Inc., a late-stage clinical biotechnology company developing therapies for cardiometabolic and other diseases, today announced that it is attending the ESC Congress 2026 in Munich.
The ESC congress is held annually and represents the flagship event of the European Society of Cardiology, bringing together thousands of cardiology professionals worldwide to share knowledge, research, and innovations in cardiovascular medicine.
The event is taking place on August 28-31, 2026 in Munich.
Recardio is participating and presenting its latest advancements from its drug-based regenerative therapy and is giving a future outlook on new therapies and expansion programs.
About Recardio
Recardio Inc. is a late-stage clinical biotechnology company focused on developing therapies for cardiometabolic and other diseases through a therapeutic platform, designed for disease modification and regeneration.
The company is located in San Francisco, California, with operations in the USA and Europe.
Recardio’s lead drug candidate, dutogliptin, a DPP-IV inhibitor, has demonstrated efficacy in promoting endogenous disease-modifying cardiac regeneration and supporting tissue repair following cardiac injury. The FDA and EMA have approved the global pivotal Phase 3 HEAL-AMI clinical program in acute myocardial infarction for regulatory authorization in major markets.
In addition, the company is advancing multiple cardiometabolic programs in clinical and preclinical development.
For more information, visit: www.recardio.eu or contact pr@recardio.eu
